Newton Biocapital

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.

AdipoPharma SAS focuses on advancing treatments for insulin resistance and type 2 diabetes by harnessing the unique properties of adipocyte cells. The company develops peptide-based drugs aimed at improving insulin sensitivity and controlling blood glucose levels in patients. AdipoPharma's approach involves a comprehensive genetic analysis of conditions such as Alström syndrome and utilizes therapeutic peptides that target specific pathways to enhance lipid biosynthesis in diseased adipocytes. This targeted methodology not only addresses insulin resistance but also aims to reduce liver fibrosis and steatosis, offering low-risk treatment options for individuals managing diabetes and its associated comorbidities.

AbolerIS Pharma is a biotechnology company based in Nantes, France, focused on developing immune-modulators for the treatment of transplant rejection, graft-versus-host disease, and autoimmune diseases. Established in 2019, the company employs a unique therapeutic approach that aims to induce immune tolerance while preserving beneficial immune responses in various inflammatory and degenerative conditions. Its product portfolio includes Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma's innovative strategies enable researchers to advance novel drug development in areas with significant unmet medical needs.

Santero Therapeutics is focused on developing innovative antibiotics aimed at addressing the challenges posed by multi-drug-resistant pathogens. The company creates medications that employ novel mechanisms of action to effectively combat infections resistant to traditional treatments. By providing therapies that maintain prolonged efficacy, Santero aims to improve patient outcomes and offer better-tolerated options for those afflicted with difficult-to-treat infections. Through its research and development efforts, Santero Therapeutics seeks to contribute to the fight against antibiotic resistance, a growing concern in modern medicine.

AdipoPharma SAS focuses on advancing treatments for insulin resistance and type 2 diabetes by harnessing the unique properties of adipocyte cells. The company develops peptide-based drugs aimed at improving insulin sensitivity and controlling blood glucose levels in patients. AdipoPharma's approach involves a comprehensive genetic analysis of conditions such as Alström syndrome and utilizes therapeutic peptides that target specific pathways to enhance lipid biosynthesis in diseased adipocytes. This targeted methodology not only addresses insulin resistance but also aims to reduce liver fibrosis and steatosis, offering low-risk treatment options for individuals managing diabetes and its associated comorbidities.

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in genome editing alternatives and offers advanced tools for RNA molecule editing, utilizing pentatricopeptide repeat (PPR) protein engineering technologies. EditForce's innovations focus on manipulating nucleic acids, specifically DNA and RNA, to facilitate research and development in various fields, including biological research, medicine, agriculture, and bio-production. Their technology allows for precise targeting of base sequences in nucleic acids, enabling significant advancements in drug development and seed research.

DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

AbolerIS Pharma is a biotechnology company based in Nantes, France, focused on developing immune-modulators for the treatment of transplant rejection, graft-versus-host disease, and autoimmune diseases. Established in 2019, the company employs a unique therapeutic approach that aims to induce immune tolerance while preserving beneficial immune responses in various inflammatory and degenerative conditions. Its product portfolio includes Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma's innovative strategies enable researchers to advance novel drug development in areas with significant unmet medical needs.

J-Pharma is a pharmaceutical company focused on developing novel drugs through a human-genomic approach, specifically targeting cell membrane transporters associated with various diseases. The company aims to create selective agents for treating conditions such as cancer by developing anti-cancer drugs and PET diagnostic agents that interact with transporters like LAT1, which are linked to cancer cell growth. J-Pharma's research emphasizes the importance of understanding drug transporters to enhance the pharmacokinetics of new drug candidates. By discovering key transporters within the human body, J-Pharma seeks to advance diagnostic methods and improve treatment options, thereby contributing to global health and enhancing the quality of life for aging populations in industrialized countries.

EditForce Inc. is a biotechnology company based in Fukuoka, Japan, founded in 2015. The company specializes in genome editing alternatives and offers advanced tools for RNA molecule editing, utilizing pentatricopeptide repeat (PPR) protein engineering technologies. EditForce's innovations focus on manipulating nucleic acids, specifically DNA and RNA, to facilitate research and development in various fields, including biological research, medicine, agriculture, and bio-production. Their technology allows for precise targeting of base sequences in nucleic acids, enabling significant advancements in drug development and seed research.

Acticor Biotech is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the urgent need for effective therapies in the acute phase of ischemic stroke, a condition that affects approximately 15 million people globally each year, leading to significant mortality and disability. Currently, there is a lack of effective treatment options, with existing therapies demonstrating limited efficacy and accessibility. Acticor Biotech seeks to provide innovative solutions to improve outcomes for stroke patients, addressing a critical gap in current medical care.

Acticor Biotech is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the urgent need for effective therapies in the acute phase of ischemic stroke, a condition that affects approximately 15 million people globally each year, leading to significant mortality and disability. Currently, there is a lack of effective treatment options, with existing therapies demonstrating limited efficacy and accessibility. Acticor Biotech seeks to provide innovative solutions to improve outcomes for stroke patients, addressing a critical gap in current medical care.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

ChromaCure is engaged in the development of innovative cancer therapies, focusing on discovering first-in-class small molecule therapeutics to address unmet needs in oncology. The company is initiating a drug development program aimed at identifying new candidates that selectively and potently inhibit cancer targets. This initiative seeks to provide novel treatment options for multiple forms of cancer, either as standalone therapies or in combination with existing immunotherapy or chemotherapy approaches. Through its efforts, ChromaCure aims to enhance the therapeutic landscape for cancer patients, offering potential new solutions for various cancer types.

Synergia Medical, established in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in developing neurostimulation medical devices. The company is renowned for its innovative optoelectronic neurostimulator platform, which integrates biomaterials, optical components, biosensors, and microelectronics. Synergia's mission is to commercialize next-generation neurostimulation devices, led by a seasoned management team with extensive experience in developing implantable neurostimulators. In a short span of three years, the company achieved ISO13485 certification, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm, and developed its first version of the NAOS platform. Backed by private investors and public research grants, Synergia has grown to a team of thirteen highly skilled multidisciplinary professionals, focusing on advancing medical devices for neurostimulation using optoelectronics.

Dim3 SA specializes in the development and marketing of clinical expert platforms and medical devices aimed at improving clinical nutrition management. The company's offerings include Scorso, an application designed for the screening and monitoring of disease-related malnutrition; Nutrow, a decision support software that optimizes clinical nutrition; and Biocorder, a mobile clinical assistant. Founded in 2013 and based in Beaufays, Belgium, Dim3 addresses the critical issue of disease-related malnutrition, which poses significant health risks and incurs substantial costs in healthcare. By providing real-time assessments of patients' nutritional status and needs through scientific algorithms, Dim3 enables healthcare professionals to make timely and effective decisions that enhance patient outcomes while reducing overall healthcare expenses.